Literature DB >> 15641052

Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus.

Patrick Blanco1, Vincent Pitard, Jean-François Viallard, Jean-Luc Taupin, Jean-Luc Pellegrin, Jean-François Moreau.   

Abstract

OBJECTIVE: Cytotoxic T lymphocyte-mediated killing using granzyme B has recently been proposed to be a preferential and selective source of autoantigens in systemic autoimmune diseases, including systemic lupus erythematosus (SLE), while other reports have indicated that cytolytic activity in SLE patients was decreased. The aim of this study was to examine the phenotypic and functional status of the CD8+ T cells in SLE patients.
METHODS: Phenotype analysis of CD8+ T cells was carried out using flow cytometry. The cytotoxic potential of CD8+ T cells and its consequences were examined in redirected-killing experiments. SLE patients with quiescent disease (n = 41) were compared with SLE patients with active disease (n = 20), normal individuals (n = 36), and control patients with vasculitis (n = 14). Cytotoxic CD8+ T cell differentiation was examined by coculture with differentiated dendritic cells (DCs) in the presence of SLE patient sera.
RESULTS: Patients with disease flares were characterized by higher proportions of perforin- and/or granzyme B-positive lymphocytes with a differentiated effector phenotype (CCR7- and CD45RA+). The frequency of these cells in peripheral blood correlated with clinical disease activity as assessed by the SLE Disease Activity Index. These cells generated high amounts of soluble nucleosomes as well as granzyme B-dependent unique autoantigen fragments. Finally, the activation of DCs with serum from a patient with active lupus induced granzyme B expression in CD8+ T lymphocytes.
CONCLUSION: DCs generated in the presence of sera from SLE patients with active disease could promote the differentiation of CD8+ effector T lymphocytes that are fully functional and able to generate SLE autoantigens. Our data disclose a new and pivotal role of activated CD8+ T lymphocytes in SLE pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15641052     DOI: 10.1002/art.20745

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  78 in total

1.  IL-7Rαlow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus.

Authors:  Jung-Sik Kim; Bon-A Cho; Ji Hyun Sim; Kamini Shah; Connie M Woo; Eun Bong Lee; Dong-Sup Lee; Jae Seung Kang; Wang Jae Lee; Chung-Gyu Park; Joe Craft; Insoo Kang; Hang-Rae Kim
Journal:  Rheumatology (Oxford)       Date:  2012-06-01       Impact factor: 7.580

Review 2.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

3.  Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4-Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus.

Authors:  Katalin Kis-Toth; Denis Comte; Maria P Karampetsou; Vasileios C Kyttaris; Lakshmi Kannan; Cox Terhorst; George C Tsokos
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

Review 4.  Dendritic cells and cytokines in human inflammatory and autoimmune diseases.

Authors:  Patrick Blanco; A Karolina Palucka; Virginia Pascual; Jacques Banchereau
Journal:  Cytokine Growth Factor Rev       Date:  2008-02       Impact factor: 7.638

Review 5.  Autoantigens in systemic autoimmunity: critical partner in pathogenesis.

Authors:  A Rosen; L Casciola-Rosen
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

Review 6.  Type I interferons: crucial participants in disease amplification in autoimmunity.

Authors:  John C Hall; Antony Rosen
Journal:  Nat Rev Rheumatol       Date:  2010-01       Impact factor: 20.543

7.  Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.

Authors:  César Díaz-Torné; M Angels Ortiz de Juana; Carme Geli; Elisabet Cantó; Ana Laiz; Héctor Corominas; Jordi Casademont; Josep M de Llobet; Cándido Juárez; César Díaz-López; Sílvia Vidal
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 8.  Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review.

Authors:  Kam Hon Yoon
Journal:  J Biomed Biotechnol       Date:  2010-06-28

9.  The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.

Authors:  Linda A Lieberman; George C Tsokos
Journal:  J Biomed Biotechnol       Date:  2010-06-06

10.  Self-organized criticality theory of autoimmunity.

Authors:  Ken Tsumiyama; Yumi Miyazaki; Shunichi Shiozawa
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.